Recent 8-K filings for DCOY

• June 29, 2026, 6:03 AM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01

  Decoy Therapeutics raises $3.5M upfront in PIPE, up to $21M with milestone warrants

  Gross proceeds of $3.5M from sale of 592,217 shares (or pre-funded warrants) at $5.91/share.

• April 2, 2026, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split

  Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.

• March 5, 2026, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 8.01item 9.01 ◈ Governance Changes

  Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

  Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.

• February 25, 2026, 6:59 PM ET other material materiality 0.60 neutral item 5.07

  Decoy Therapeutics shareholders approve 2026 equity plan and reverse stock split

  Approved 2026 Equity Incentive Plan: 351,837 for, 68,978 against, 55,703 abstentions.

• January 2, 2026, 6:59 PM ET regulatory materiality 0.90 negative item 3.01 ◈ Listing & Compliance Notices

  Salarius receives Nasdaq delisting notice for bid price non-compliance; appeal planned

  Nasdaq notified Salarius on Dec 31, 2025 that bid price closed below $1.00 for 30 consecutive days.

• November 17, 2025, 6:59 PM ET regulatory materiality 0.60 neutral item 7.01

  Salarius Pharmaceuticals corrects false delisting reports; remains listed on Nasdaq

  Company statement that stock continues trading on Nasdaq Capital Market under ticker SLRX despite inaccurate Yahoo Finance and CapIQ delisting reports.

• November 13, 2025, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 2.01item 3.02item 3.03item 5.03item 5.02item 8.01item 9.01 ◈ M&A Transactions

  Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering

  Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.

• October 14, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger

  Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).

• October 6, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Salarius raises $6.2M; believes Nasdaq equity compliance regained ahead of Oct 20 deadline

  Raised $2.4M from ATM sales (434,882 shares) and $3.8M from C/M Capital Master Fund purchase agreement.

• September 18, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 1.01item 3.03item 9.01 ◈ Equity Issuances

  Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75

  Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.

• September 9, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing

  Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.

• August 27, 2025, 7:59 PM ET regulatory materiality 0.90 negative item 8.01

  Salarius Pharmaceuticals receives Nasdaq extension to regain equity compliance by Oct 20, 2025

  Nasdaq Hearings Panel granted Salarius until October 20, 2025 to comply with the Equity Standard (Rule 5550(b)(1)).

• August 26, 2025, 7:59 PM ET M&A materiality 0.75 negative item 9.01

  Salarius amends merger with Decoy; legacy holders diluted to 7.6%

  Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).

• August 22, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 8.01item 9.01

  Salarius-Decoy merger update: legacy holders ~7.6% stake, $6M minimum financing required

  Step one: Decoy stockholders receive ~92.4% of Salarius; legacy holders ~7.6% based on exchange ratio.

• August 18, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Salarius Pharma CEO David J. Arthur resigns; CFO Mark J. Rosenblum named acting CEO

  David J. Arthur resigned as CEO effective Aug 17, 2025; not due to any disagreement with the company.

• July 29, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 1.01item 3.03item 9.01

  Salarius amends Decoy merger: removes $2M threshold, changes conversion price adjustment

  Fourth Amendment dated July 29, 2025 removes $2M threshold for 'subsequent financing' triggering conversion adjustment.

• July 28, 2025, 7:59 PM ET other material materiality 0.75 negative item 8.01

  Nasdaq Hearings Panel grants SLRX additional extension to regain listing compliance by August 2025

  Equity Standard compliance deadline extended to mid-August 2025 from late July.

• July 14, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 8.01item 9.01

  Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance

  Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.

• July 8, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

  Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance

  Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.

• June 16, 2025, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01

  Salarius gets Nasdaq extension to regain listing compliance; milestones set for July/August 2025

  Nasdaq Hearings Panel granted extension to comply with Minimum Bid Price and Equity Standards.

• June 11, 2025, 7:59 PM ET M&A materiality 0.85 negative item 1.01item 9.01

  Salarius cuts merger valuation from $4.6M to $2.31M; legacy holders drop to 7.6%

  Parent Valuation reduced to $2.31M, down from $4.6M in original Jan 2025 merger agreement.

• April 25, 2025, 7:59 PM ET regulatory materiality 0.90 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Salarius Pharma receives Nasdaq delisting notice for bid price non-compliance; merger with Decoy planned

  Nasdaq notice on April 23, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.

• March 28, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 1.01item 3.01item 9.01 ◈ Listing & Compliance Notices

  Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall

  Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.

• January 13, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 1.01item 3.02item 7.01item 8.01item 9.01

  Salarius to merge with Decoy; Decoy valued at $28M, legacy holders ~14.1% ownership

  Merger structured as stock-for-stock with Decoy valued at $28M and Salarius at $4.6M, based on cash at close.

• December 13, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Salarius enters $10M equity purchase agreement with C/M Capital Fund

  Up to $10M of common stock may be sold over 36 months at 95% of VWAP or closing price.

• August 15, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01

  Salarius raises ~$1.5M to meet Nasdaq minimum equity requirement after being below $2.5M threshold

  As of June 30, 2024, stockholders' equity was $2,375,353, below Nasdaq's $2.5M minimum.

• July 19, 2024, 7:59 PM ET other material materiality 0.75 negative item 8.01

  Salarius closes Phase 1/2 seclidemstat Ewing sarcoma trial; explores strategic alternatives

  Company terminates ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma to conserve cash.

• July 11, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 8.01

  Salarius Pharmaceuticals announces FDA partial clinical hold on seclidemstat trial after grade 4 adverse event

  A patient in MDACC's trial of seclidemstat + azacitidine for MDS/CMML experienced a serious unexpected grade 4 adverse event.

• June 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024

  Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.

• March 6, 2024, 6:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Salarius Pharma gets Nasdaq extension to Sep 3 for bid price compliance; will pursue reverse split if needed

  Nasdaq granted Salarius until Sep 3, 2024 to regain $1.00 minimum bid price compliance.

• February 23, 2024, 6:59 PM ET other material materiality 0.75 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  Salarius extends cash runway into H1 2025; CEO Arthur transitions to part-time consultant

  CEO David Arthur ends full-time employment; becomes part-time consultant effective Feb 20, 2024, at $10,417/month.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

4 positive 12 negative 34 neutral

source · DCOY on sec.gov